Last edition
News about "Samsung Bioepis"
Samsung Biologics has announced its financial results for the second quarter of fiscal year 2025, posting strong growth across both consolidated and standalone metrics.
Samsung Bioepis | 23/07/2025 | By Dineshwori | 614
Samsung Bioepis Partners with Harrow for US Commercialisation of Ophthalmology Biosimilars
Following the transition of commercial rights from Biogen back to Samsung Bioepis, Harrow will assume full responsibility for the commercialisation of both BYOOVIZ and OPUVIZ biosimilars in the US.
Samsung Bioepis | 18/07/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy